Heron Therapeuti is a biotechnology business based in the US. Heron Therapeuti shares (HRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Heron Therapeuti employs 302 staff and has a trailing 12-month revenue of around $95 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $3.98 |
|---|---|
| 52-week range | $2.19 - $12.89 |
| 50-day moving average | $3.92 |
| 200-day moving average | $5.58 |
| Wall St. target price | $15.08 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.29 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.98 from 2022-09-23
| 1 week (2022-09-16) | -14.78% |
|---|---|
| 1 month (2022-08-25) | -18.11% |
| 3 months (2022-06-24) | 17.06% |
| 6 months (2022-03-24) | -29.68% |
| 1 year (2021-09-24) | -68.39% |
|---|---|
| 2 years (2020-09-25) | -72.76% |
| 3 years (2019-09-25) | 19.16 |
| 5 years (2017-09-25) | 15.45 |
| Revenue TTM | $95 million |
|---|---|
| Gross profit TTM | $-90,496,000 |
| Return on assets TTM | -41.97% |
| Return on equity TTM | -328.53% |
| Profit margin | -239.34% |
| Book value | $0.24 |
| Market capitalisation | $554.6 million |
TTM: trailing 12 months
We're not expecting Heron Therapeuti to pay a dividend over the next 12 months.
Heron Therapeuti's shares were split on a 1:20 basis on 12 January 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heron Therapeuti shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Heron Therapeuti shares which in turn could have impacted Heron Therapeuti's share price.
Over the last 12 months, Heron Therapeuti's shares have ranged in value from as little as $2.19 up to $12.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heron Therapeuti's is 1.1438. This would suggest that Heron Therapeuti's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Heron Therapeutics, Inc. , a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A. P.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.